pathfndr header uai

This webinar is intended for U.S. Healthcare Professionals only

Hear Peter Trainer, MD, David Clemmons MD, and other experts from Crinetics Pharmaceuticals discuss paltusotine, an investigational treatment for acromegaly.

Also learn about the Phase 3 PATHFNDR studies for paltusotine now underway.

Our drug candidate, paltusotine, is a ONCE DAILY, ORAL treatment. If approved, it would establish a new class of oral, selective, nonpeptide, somatostatin receptor type 2 (SST2) agonists designed for the treatment of acromegaly. Our Phase 3 studies are now underway and enrolling participants.

Advancing Acromegaly Treatment
Webinar for U.S. Healthcare Professionals


  • The need for new acromegaly therapies
  • Overview of investigational paltusotine
  • PATHFNDR studies and Phase 2/OLE interim findings
  • Q&A with Crinetics leaders


peter trainer, md, frscp, vp, clinical endocrinology

Peter Trainer, MD, FRSCP
VP, Clinical Endocrinology

david clemmons, md, scientific advisor

David Clemmons, MD
Scientific Advisor

alessandra casagrande, md, phd, medical sciences director

Alessandra Casagrande, MD, PhD
Medical Sciences Director

alan krasner, md, chief medical officer

Alan S. Krasner, MD
Chief Medical Officer

Now Recruiting for Phase 3

The PATHFNDR studies are now underway and recruiting participants. These Phase 3, randomized, placebo-controlled, multi-center studies are evaluating the safety and efficacy of paltusotine, an investigational treatment for patients with acromegaly. Paltusotine was shown in Phase 2 studies to maintain IGF-1 levels in patients with acromegaly who were previously on octreotide LAR or lanreotide depot monotherapy.

Click below for key study eligibility/exclusion criteria and additional information.

Learn More

If you have patients with acromegaly who might consider participating in the PATHFNDR studies, download a Referral Toolkit which includes convenient resources that make it easy to refer acromegaly patients to the PATHFNDR studies.

Get Toolkit